With over 2.16 million MaxCyte Inc. (MXCT) shares trading Friday and a closing price of $3.83 on the day, the dollar volume was approximately $8.29 million. The shares have shown a negative half year performance of -42.84% and its price on 05/19/23 gained nearly 2.13%. Currently, there are 102.85M common shares owned by the public and among those 96.75M shares have been available to trade.
Insiders at the company have transacted a total of 70 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 36 of these insider trades were purchases, accounting for 483,932 shares. Insider sales of the common stock occurred on 34 occasions, with total insider shares sold totaling 4,295,266 shares.
Unlock the Hottest Top 10 Penny Stocks Today! Discover Now
Dive into the world of lucrative penny stocks with MarketClub's groundbreaking "Smart Scan" technology! Get an instant snapshot of the top 50 high volume stocks with a clear direction and outstanding liquidity - in other words, the strongest trending. To unlock this exclusive list, simply provide your first name, last name, and email for instant access.
Gain Access to Top 10 Penny Stocks Now!.
Sponsored
The top 3 mutual fund holders in MaxCyte Inc. are Vanguard Total Stock Market ETF, Unicorn AIM VCT Plc, and iShares Russell 2000 ETF. Vanguard Total Stock Market ETF owns 2.8 million shares of the company’s stock, all valued at over $13.56 million. iShares Russell 2000 ETF sold 27200.0 shares to bring its total holdings to over 1.86 million shares at a value of $9.01 million. iShares Russell 2000 ETF now owns shares totaling to 1.81% of the shares outstanding.
Shares of MaxCyte Inc. (NASDAQ: MXCT) opened at $3.84, up $0.09 from a prior closing price of $3.75. However, the script later moved the day high at 3.8600, up 2.13%. The company’s stock has a 5-day price change of 0.13% and -21.03% over the past three months. MXCT shares are trading -29.85% year to date (YTD), with the 12-month market performance down to -13.93% lower. It has a 12-month low price of $3.36 and touched a high of $7.50 over the same period. MXCT has an average intraday trading volume of 556.17K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -14.74%, -16.43%, and -29.84% respectively.
Institutional ownership of MaxCyte Inc. (NASDAQ: MXCT) shares accounts for 85.40% of the company’s 102.85M shares outstanding. Mutual fund holders own –, while other institutional holders and individual stakeholders account for — and — respectively.
It has a market capitalization of $386.41M. The earnings-per-share (ttm) stands at -$0.30. Price movements for the stock have been influenced by the stock’s volatility, which stands at 5.57% over the week and 5.17% over the month.
Analysts forecast that MaxCyte Inc. (MXCT) will achieve an EPS of -$0.1 for the current quarter, -$0.08 for the next quarter and -$0.29 for 2024. The lowest estimate earnings-per-share for the quarter is -$0.12 while analysts give the company a high EPS estimate of -$0.08. Comparatively, EPS for the current quarter was -$0.08 a year ago. Earnings per share for the fiscal year are expected to decrease by -10.10%, and 9.40% over the next financial year.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 7 brokerage firm advisors rate MaxCyte Inc. (MXCT) as a “Strong Buy” at a consensus score of 1.30. Specifically, 7 Wall Street analysts polled rate the stock as a buy, while 0 of the 7 advise that investors “hold,” and 0 rated it as a “Sell.”
